Benralizumab Proves Noninferior to Mepolizumab for EGPA Benralizumab Proves Noninferior to Mepolizumab for EGPA

Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs.MDedge News

Source: Medscape Medical News Headlines - November 28, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news